CDISC Standards for Clinical Trial Data
*Chris Holland, FDA 


Members of industry and the FDA are increasingly encouraging the implementation of CDISC standards for clinical trial data. While some organizations have adapted completely to the use of such standards, others have decided to take a “wait and see” approach. Thoughts and experiences from both ends of the spectrum, including those from FDA, are invited to be shared at this roundtable so that participants can decide whether they have jumped in too early, or are jumping in too late.